- Home
- NP vs DNLI Comparison
NP vs DNLI Comparison
Compare NP & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NP | DNLI |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | 60 | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.7B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | NP | DNLI |
|---|---|---|
| Price | $29.03 | $24.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $28.17 | ★ $34.33 |
| AVG Volume (30 Days) | 664.7K | ★ 1.8M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.84 | N/A |
| Revenue Next Year | $15.80 | $408.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.78 | $12.58 |
| 52 Week High | $31.75 | $25.31 |
Technical Indicators
Market Signals| Indicator | NP | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 62.23 | 74.12 |
| Support Level | $24.09 | $18.27 |
| Resistance Level | $31.63 | N/A |
| Average True Range (ATR) | 1.26 | 1.24 |
| MACD | 0.37 | 0.44 |
| Stochastic Oscillator | 90.60 | 88.15 |
Price Performance
Historical ComparisonAbout NP Neptune Insurance Holdings Inc.
Neptune Insurance Holdings Inc is a high-growth, profitable, data-driven MGA that offers residential and commercial insurance products, including primary flood insurance, excess flood insurance and parametric earthquake insurance, distributed through a nationwide network of agencies in the United States. The company underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies and does not take any balance sheet insurance risk or have claims handling responsibility relating to the policies it sells.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.